N,N-dicyclohexylbenzothiazole-2-sulphenamide

Basic toxicokinetics

Administrative data

Endpoint:

basic toxicokinetics

Type of information:

other: assumption toxicokinetics

Adequacy of study:

supporting study

Reliability:

other: assumption toxicokinetics

Rationale for reliability incl. deficiencies:

other: assumption: toxicokinetics DCBS, which based on physico-chemical data and acute and repeated dose toxicity data of DCBS

Data source

Reference

Reference 1

Reference Type:

study report

Title:

Unnamed

Year:

1989

Report date:

1989

Reference 2

Reference Type:

study report

Title:

Unnamed

Year:

1988

Report date:

1988

Reference 3

Reference Type:

study report

Title:

Unnamed

Year:

1985

Report date:

1985

Reference 4

Reference Type:

other: OECD SIDS

Title:

N,N-dicyclohexyl-2-benzothiazolessulfenamide, CAS 4979-32-2, SIDS Inital Assessment Report

Author:

OECD SIDS

Year:

2004

Bibliographic source:

OECD SIDS, SIDS Inital Assessment Report, UNEP Publications

Materials and methods

Principles of method if other than guideline:

assumption toxicokinetic of DCBS, which based on physico-chemical data and acute and repeated dose toxicity data of DCBS

GLP compliance:

no

Test material

Test material information

Constituent 1

Reference substance name:

N,N-dicyclohexylbenzothiazole-2-sulphenamide

EC Number:

225-625-8

EC Name:

N,N-dicyclohexylbenzothiazole-2-sulphenamide

Cas Number:

4979-32-2

Molecular formula:

C19H26N2S2

IUPAC Name:

N-(1,3-benzothiazol-2-ylsulfanyl)-N-cyclohexylcyclohexanamine

Results and discussion

Main ADME results

Type:

other:

Results:

assumption: toxicokinetics

Any other information on results incl. tables

There are no study data available for the toxicokinetic of the test substance N, N-dicyclohexyl-2-benzothiazolesulfenamide (DCBS.) However, considering the experiences with DCBS in acute and repeated dose toxicity studies, a characterization of DCBS toxicokinetics can be conducted.

DCBS is a solid powder with a low vapour pressure < 7.0 x 10^-5Pa at 100 °C (OECD SIDS 2004); therefore inhalation exposure to the vapour might be negligible.

DCBS is practically insoluble in water (1.9 µg/l at 25°C). However, the molecular mass of 346.59 g/mol and the n-octanol/water coefficient (log Pow of > 4.80 at 25°C) suggest intestinal absorption subsequent to oral ingestion.

This assumption is confirmed by data from acute oral toxicity studies and repeated dose toxicity studies. However, acute toxicity is low because LD50 values are high (greater than 5000 mg/kg bw, Monsanto 1985); systemic availability was indicated by clinical signs like hypoactive, decreased food consumption, and other abnormalities (nasal discharge, oral discharge, wet rales, ocular discharge, urinary straining, unthrifty coat, soft stool, and eyes closed). In addition, studies with repeated oral dosing of rats indicating bioavailability of the compound by showing dose related toxic effects like a decrease in body weight gain and food consumption (Monsanto 1988, 1989).

The dermal toxicity is very low, indicated by a dermal LD50 greater than 5000 mg/ kg bw (Monsanto 1985). New Zealand White rabbits were dosed with 5000 mg/ kg bw. A 14-day observation period followed application. No mortality was observed. Most animals were free of signs of systemic toxicity, although several occurrences of nasal discharge were seen, primarily in a single animal, and a few occurrences of ocular irritation were noted in another animal. Gross postmortem observations were similar to those seen in control animals in this laboratory or were considered to represent normal physiological variation. Based on these findings the authors concluded that the LD50 is greater than 5000 mg/kg bw (Monsanto 1985).